Financhill
Sell
40

ZLDPF Quote, Financials, Valuation and Earnings

Last price:
$63.42
Seasonality move :
18.35%
Day range:
$62.20 - $62.20
52-week range:
$57.97 - $141.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
533.08x
P/B ratio:
3.65x
Volume:
--
Avg. volume:
845
1-year change:
-28.96%
Market cap:
$4.4B
Revenue:
$9.1M
EPS (TTM):
-$2.49

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZLDPF
Zealand Pharma AS
$32.7M -- 23693.73% -- --
ASND
Ascendis Pharma AS
$107.9M -$1.71 292.42% -21.89% $220.68
EVAX
Evaxion Biotech AS
$60K -$0.71 -59.42% -91.42% $13.25
GLTO
Galecto
-- -$2.82 -- -51.46% $8.00
GMAB
Genmab AS
$759.6M $0.23 17.06% 32.58% $29.31
NVO
Novo Nordisk AS
$11.9B $0.92 18.85% 36.74% $89.76
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZLDPF
Zealand Pharma AS
$62.20 -- $4.4B -- $0.00 0% 533.08x
ASND
Ascendis Pharma AS
$160.33 $220.68 $9.7B -- $0.00 0% 23.88x
EVAX
Evaxion Biotech AS
$1.71 $13.25 $10.8M -- $0.00 0% 0.54x
GLTO
Galecto
$3.07 $8.00 $4.1M -- $0.00 0% --
GMAB
Genmab AS
$20.18 $29.31 $12.5B 12.00x $0.00 0% 4.23x
NVO
Novo Nordisk AS
$67.02 $89.76 $297.8B 19.85x $1.10 2.41% 6.85x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZLDPF
Zealand Pharma AS
3.37% 1.941 0.79% 24.39x
ASND
Ascendis Pharma AS
128.87% 0.179 9.75% 0.67x
EVAX
Evaxion Biotech AS
-- -0.376 -- 2.80x
GLTO
Galecto
-- 1.269 -- --
GMAB
Genmab AS
-- 0.045 -- 5.32x
NVO
Novo Nordisk AS
46.15% 1.792 5.59% 0.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZLDPF
Zealand Pharma AS
$1.1M -$57.4M -14.95% -15.5% -4066.58% -$71.8M
ASND
Ascendis Pharma AS
$87.8M -$109.7M -59.13% -880.05% -48.32% -$90.9M
EVAX
Evaxion Biotech AS
-- -$1.7M -238.97% -- -54.59% --
GLTO
Galecto
-- -$2.6M -- -- -- -$2.4M
GMAB
Genmab AS
$673M $188M 22.23% 22.23% 34.83% $257M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B

Zealand Pharma AS vs. Competitors

  • Which has Higher Returns ZLDPF or ASND?

    Ascendis Pharma AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of -93.73%. Zealand Pharma AS's return on equity of -15.5% beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZLDPF
    Zealand Pharma AS
    95% -$0.67 $1.2B
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About ZLDPF or ASND?

    Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Ascendis Pharma AS has an analysts' consensus of $220.68 which suggests that it could grow by 37.64%. Given that Ascendis Pharma AS has higher upside potential than Zealand Pharma AS, analysts believe Ascendis Pharma AS is more attractive than Zealand Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZLDPF
    Zealand Pharma AS
    0 0 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is ZLDPF or ASND More Risky?

    Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

  • Which is a Better Dividend Stock ZLDPF or ASND?

    Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZLDPF or ASND?

    Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Zealand Pharma AS's net income of -$47.3M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 23.88x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZLDPF
    Zealand Pharma AS
    533.08x -- $1.1M -$47.3M
    ASND
    Ascendis Pharma AS
    23.88x -- $106.2M -$99.6M
  • Which has Higher Returns ZLDPF or EVAX?

    Evaxion Biotech AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of -64.14%. Zealand Pharma AS's return on equity of -15.5% beat Evaxion Biotech AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZLDPF
    Zealand Pharma AS
    95% -$0.67 $1.2B
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
  • What do Analysts Say About ZLDPF or EVAX?

    Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 674.9%. Given that Evaxion Biotech AS has higher upside potential than Zealand Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Zealand Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZLDPF
    Zealand Pharma AS
    0 0 0
    EVAX
    Evaxion Biotech AS
    1 0 0
  • Is ZLDPF or EVAX More Risky?

    Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ZLDPF or EVAX?

    Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZLDPF or EVAX?

    Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Evaxion Biotech AS quarterly revenues of $3M. Zealand Pharma AS's net income of -$47.3M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 0.54x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZLDPF
    Zealand Pharma AS
    533.08x -- $1.1M -$47.3M
    EVAX
    Evaxion Biotech AS
    0.54x -- $3M -$1.9M
  • Which has Higher Returns ZLDPF or GLTO?

    Galecto has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of --. Zealand Pharma AS's return on equity of -15.5% beat Galecto's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZLDPF
    Zealand Pharma AS
    95% -$0.67 $1.2B
    GLTO
    Galecto
    -- -$1.92 --
  • What do Analysts Say About ZLDPF or GLTO?

    Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Galecto has an analysts' consensus of $8.00 which suggests that it could grow by 160.59%. Given that Galecto has higher upside potential than Zealand Pharma AS, analysts believe Galecto is more attractive than Zealand Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZLDPF
    Zealand Pharma AS
    0 0 0
    GLTO
    Galecto
    1 1 0
  • Is ZLDPF or GLTO More Risky?

    Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ZLDPF or GLTO?

    Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZLDPF or GLTO?

    Zealand Pharma AS quarterly revenues are $1.1M, which are larger than Galecto quarterly revenues of --. Zealand Pharma AS's net income of -$47.3M is lower than Galecto's net income of -$2.5M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZLDPF
    Zealand Pharma AS
    533.08x -- $1.1M -$47.3M
    GLTO
    Galecto
    -- -- -- -$2.5M
  • Which has Higher Returns ZLDPF or GMAB?

    Genmab AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of 27.27%. Zealand Pharma AS's return on equity of -15.5% beat Genmab AS's return on equity of 22.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZLDPF
    Zealand Pharma AS
    95% -$0.67 $1.2B
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
  • What do Analysts Say About ZLDPF or GMAB?

    Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Genmab AS has an analysts' consensus of $29.31 which suggests that it could grow by 45.26%. Given that Genmab AS has higher upside potential than Zealand Pharma AS, analysts believe Genmab AS is more attractive than Zealand Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZLDPF
    Zealand Pharma AS
    0 0 0
    GMAB
    Genmab AS
    4 4 0
  • Is ZLDPF or GMAB More Risky?

    Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.676%.

  • Which is a Better Dividend Stock ZLDPF or GMAB?

    Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZLDPF or GMAB?

    Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Genmab AS quarterly revenues of $715M. Zealand Pharma AS's net income of -$47.3M is lower than Genmab AS's net income of $195M. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Genmab AS's PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 4.23x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZLDPF
    Zealand Pharma AS
    533.08x -- $1.1M -$47.3M
    GMAB
    Genmab AS
    4.23x 12.00x $715M $195M
  • Which has Higher Returns ZLDPF or NVO?

    Novo Nordisk AS has a net margin of -4144.13% compared to Zealand Pharma AS's net margin of 37.18%. Zealand Pharma AS's return on equity of -15.5% beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZLDPF
    Zealand Pharma AS
    95% -$0.67 $1.2B
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About ZLDPF or NVO?

    Zealand Pharma AS has a consensus price target of --, signalling downside risk potential of -63.82%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 34.02%. Given that Novo Nordisk AS has higher upside potential than Zealand Pharma AS, analysts believe Novo Nordisk AS is more attractive than Zealand Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZLDPF
    Zealand Pharma AS
    0 0 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is ZLDPF or NVO More Risky?

    Zealand Pharma AS has a beta of 0.924, which suggesting that the stock is 7.579% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

  • Which is a Better Dividend Stock ZLDPF or NVO?

    Zealand Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.41% to investors and pays a quarterly dividend of $1.10 per share. Zealand Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZLDPF or NVO?

    Zealand Pharma AS quarterly revenues are $1.1M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Zealand Pharma AS's net income of -$47.3M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Zealand Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 19.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma AS is 533.08x versus 6.85x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZLDPF
    Zealand Pharma AS
    533.08x -- $1.1M -$47.3M
    NVO
    Novo Nordisk AS
    6.85x 19.85x $11B $4.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Why Mobileye Might Be Wall Street’s Next Big Surprise
Why Mobileye Might Be Wall Street’s Next Big Surprise

The trend to automate vehicles started long ago when adding…

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
99
SOC alert for May 20

Sable Offshore [SOC] is down 0.79% over the past day.

Buy
52
RGC alert for May 20

Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.

Sell
40
GWLIF alert for May 20

Great-West Lifeco [GWLIF] is up 13.42% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock